Uterine Fibroids with Pelvic Bulk or Pressure Symptoms: Procedural and Surgical Management After GnRH Agonist or Antagonist Therapy

This protocol addresses patients with uterine fibroids causing pelvic bulk or pressure symptoms in whom first-line medical management with a GnRH agonist or antagonist did not achieve the expected degree of fibroid shrinkage or adequate symptom relief, and procedural or surgical intervention is the appropriate next step.

Prior Treatment — Why Escalation Is Needed

First-line medical management with a GnRH agonist or antagonist targets a reduction in fibroid volume — up to 50% of initial volume within approximately three months — and a corresponding reduction in overall uterine volume. When these goals are not adequately met and bulk or pressure symptoms persist, the clinical situation calls for a different approach.

Next-Line Approach Partial Overview

Management at this stage centres on uterine-sparing procedural and surgical options, with the choice guided by the patient's desire to preserve fertility and/or the uterus. Both minimally invasive procedural techniques and surgical excision are part of the picture — which option is appropriate in which clinical situation, and the full sequence of decision-making, is detailed in the complete protocol.

Clinical Goals

Interventional approaches aim for substantial reductions in fibroid and uterine volume and high rates of bulk symptom relief. For example, with uterine artery embolization, expected outcomes include a 50–60% reduction in leiomyoma volume, a 40–50% reduction in uterine volume, and an 88–92% reduction in bulk symptoms. The complete protocol covers the full range of expected outcomes across available options.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jogc.2025.102970

Patients with fibroids and bulk symptoms may be offered gonadotropin-releasing hormone agonists or antagonists.
Uterine artery embolization may be offered as a minimally invasive technique that can reduce fibroid symptoms in patients wishing to preserve their uterus.
Patients should be aware that uterine artery embolization may be associated with decreased fertility, higher miscarriage rate, and adverse pregnancy outcomes, and is not advised in patients wishing for future fertility.
Radiofrequency ablation (RFA) may be offered as an option in the management of symptomatic uterine fibroids with comparable outcomes to myomectomy, with potential for decreased surgical bleeding and faster recovery.
High Intensity Focused Ultrasound (HIFU) may be offered as a minimally invasive treatment option for uterine fibroids, but it is not widely available in Canada.
In symptomatic patients wishing to preserve their fertility and/or their uterus, myomectomy may be offered.
Definitive treatment for uterine fibroids is hysterectomy.
Clinical outcomes following UAE include 50-60% reduction in leiomyoma volume, 40-50% in uterine volume, 88-92% reduction in bulk symptoms, elimination of abnormal uterine bleeding (>90%), successful elimination of symptoms (75%), and high patient satisfaction rates (80-90%).

View source ↗